Hopp til innhold
NHI.no
Annonse

Raynauds fenomen: Prognose

Innhold i artikkelen

Tilstanden er i utgangspunktet ufarlig og fører ikke til andre konsekvenser enn plager under anfallene. Mange opplever imidlertid en langsom forverring av tilstanden etter som tiden går.

Noen unge pasienter med Raynauds fenomen rådes til å ta hensyn til sykdommen ved valg av yrke. Man bør for eksempel unngå å arbeide utendørs i kulde, samt bruk av vibrerende verktøy.

Annonse

Dette dokumentet er basert på det profesjonelle dokumentet Raynauds fenomen . Referanselisten for dette dokumentet vises nedenfor

  1. Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa 2017; 46: 413-423. pmid:28895508. PubMed
  2. Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 2019; 38: 3317-3330. pmid:31420815 PubMed
  3. Goundry B, Bell L, Langtree M, Moorthy A. Diagnosis and management of Raynaud's phenomenon. BMJ 2012; 7: 344. pmid:22315243. PubMed
  4. UpToDate: Wigley FM: Clinical manifestations and diagnosis of Raynaud phenomenon, updated 17.07.23, siden lest 30.03.24 www.uptodate.com
  5. Pistorius MA, Planchon B, Schott JJ, Lemarec H.. Heredity and genetic aspects of Raynaud's disease. Send to J Mal Vasc 2006; 31: 10-5. pmid:16609626 PubMed
  6. Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol 2015; 11: 146-58. pmid:25536485 PubMed
  7. Nilsson T, Wahlström J, Burström L. Hand-arm vibration and the risk of vascular and neurological diseases-A systematic review and meta-analysis. Send to PLoS One 2017; 12: e0180795. pmid:28704466 PubMed
  8. Hughes M, Allanore Y, Chung L, et al. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 2020; 16: 208-221. pmid:32099191 PubMed
  9. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rehum Dis 2017; 76: 1327-39. pmid:27941129 PubMed
  10. Khouri C, Blaise S, Carpentier P, et al. Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol 2016; 82: 6-16. pmid:26949933 PubMed
  11. Barrett ME, Heller MM, Stone HF, Murase JE. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. JAMA Dermatol 2013; 149: 300-6. pmid:23682366 PubMed
  12. Suter LG, Murabito JM, Felson DT, Fraenkel L. Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. Am J Med 2007; 120: 264-71. PubMed
  13. Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. doi: 10.1002/14651858.CD006687.pub4. PMID: 33998674. PubMed
  14. Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. PMID: 26914257. PubMed
  15. Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. PMID: 29237099. PubMed
  16. Statens Legemiddelverk: Adalat tabletter avregistreres. Publisert 10.04.18. Nettside besøkt 08.02.19. legemiddelverket.no
  17. BMJ Best Practice: Raynauds phenomenon. Nettside besøkt 28.03.2022. bestpractice.bmj.com
  18. Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel topical nitroglycerine formulation of nitroglycerin, improves the severity of Raynaud's phenomenon, a randomized , controlled trial. Arhtritis Rheum 2009; 60: 870-7. PubMed
Annonse
Annonse